aglatimagene besadenovec — NDA/BLA submission
Q4 2026
Planning to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene) in localized, intermediate- to high-risk prostate cancer in Q4 2026Source filing
CADL biotech catalysts & pipeline
CANDEL THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
CAN-3110 (linoserpaturev) — Topline data
Q4 2026
We have recently completed enrollment in arm C and expect to present mature mOS data and an update on long-term survivors in the fourth quarter of 2026.Source filing
aglatimagene besadenovec — Conference presentation
Sep 26–Sep 30
Abstract showcasing extended biomarker data from the phase 3 clinical trial of aglatimagene in patients with localized prostate cancer to be presented as a poster at the ASTRO Annual Meeting in Q3 2026.Source filing